AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

aTYR PHARMA INC Director's Dealing 2015

May 6, 2015

34337_dirs_2015-05-06_d034574e-3cff-43a4-a843-29fcf5099718.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2015-05-06

Reporting Person: Ramsdell Fred (Vice President, Immunology)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$4.06	2024-07-10	Common Stock (34874)		Direct
Stock Option (right to buy)	$9.15	2025-04-17	Common Stock (12572)		Direct

Footnotes

F1: The shares subject to this option shall vest and become exercisable in 72 equal monthly installments beginning on June 9, 2014. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

F2: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on April 17, 2015. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.